| ATOS Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the ATOS market cap history going back to 4/20/2018:
Also see: ATOS Shares Outstanding History and ATOS YTD Return |
ATOS Market Cap History — Atossa Genetics Capitalization Over Time
As of 5/1/2026 Atossa Genetics has a market cap of 45.90 million. Investors often follow the ATOS market cap history to compare the size of the company over time.
This page shows ATOS market capitalization trends over time, with 33 market cap datapoints presented, dating back to 4/20/2018.
| ATOS Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATOS Historical Market Cap: +21.92% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ATOS Stock Price Chart |
| About Atossa Therapeutics Inc |
| Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. We show 33 historical shares outstanding datapoints in our ATOS shares outstanding history coverage, used to compute ATOS market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing ATOS market cap history over the course of time is important for investors interested in comparing ATOS's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of ATOS versus a peer is one thing; comparing ATOS market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like ATOS can fluctuate over the course of history. With this page we aim to empower investors researching ATOS by allowing them to research the ATOS market cap history. |
| ATOS Current Stock Quote |
Quotes delayed 20 minutes  Free ATOS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: The Importance of Market Cap | |
|
Video: The Importance of Market Cap
| ATOS Share Performance |
| Market Cap Peers |
| Atossa Genetics (ATOS) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
ATRA Market Cap History ATRC Market Cap History ATRI Market Cap History ATRS Market Cap History ATXI Market Cap History ATXS Market Cap History ATYR Market Cap History AURA Market Cap History AVAH Market Cap History AVBP Market Cap History More Healthcare companies » |
ATOS Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
